# A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

> **NCT00863941** · PHASE1 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Abrika Bupropion 150 mg XL Tablet, single dose
- **DRUG:** Wellbutrin XL® 150 mg Tablet, single dose

## Key facts

- **NCT ID:** NCT00863941
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2010-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00863941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00863941, "A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00863941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*